245 related articles for article (PubMed ID: 25292040)
1. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti- CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran.
Mansour-Ghanaei F; Joukar F; Rajpout Y; Hasandokht T
Asian Pac J Cancer Prev; 2014; 15(18):7635-8. PubMed ID: 25292040
[TBL] [Abstract][Full Text] [Related]
2. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.
Shafaghi A; Mansour-Ghanaei F; Joukar F; Sharafkhah M; Mesbah A; Askari K; Geranmayeh S; Mehrvarz A; Souti F; Sokhanvar H; Fakhrieh S; Aminian K; Yousefi-Mashhour M; Khosh-Sorur M; Rasoulian J
Asian Pac J Cancer Prev; 2013; 14(6):3931-6. PubMed ID: 23886209
[TBL] [Abstract][Full Text] [Related]
3. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.
Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Long Q; Flanders WD; Bostick RM; Yuan Y
Int J Cancer; 2015 Jan; 136(2):425-34. PubMed ID: 24895149
[TBL] [Abstract][Full Text] [Related]
4. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status.
Yakut M; Örmeci N; Erdal H; Keskin O; Karayel Z; Tutkak H; Soykan I
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):302-11. PubMed ID: 23137754
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in northern Iran.
Nejadi-Kelarijani F; Roshandel G; Semnani S; Ahmadi A; Faghani B; Besharat S; Akhavan-Tabib A; Amiriani T
Asian Pac J Cancer Prev; 2014; 15(17):7433-6. PubMed ID: 25227854
[TBL] [Abstract][Full Text] [Related]
6. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
[TBL] [Abstract][Full Text] [Related]
7. 'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection.
Di Mario F; Moussa AM; Caruana P; Merli R; Cavallaro LG; Cavestro GM; Dal Bò N; Iori V; Pilotto A; Leandro G; Franzè A; Rugge M
Scand J Gastroenterol; 2003 Dec; 38(12):1223-7. PubMed ID: 14750641
[TBL] [Abstract][Full Text] [Related]
8. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study.
Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Bostick RM; Wu X; Yuan Y
Am J Gastroenterol; 2017 May; 112(5):704-715. PubMed ID: 28323271
[TBL] [Abstract][Full Text] [Related]
9. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.
Con SA; Con-Wong R; Con-Chin GR; Con-Chin VG; Takeuchi H; Valerín AL; Echandi G; Mena F; Brenes F; Yasuda N; Araki K; Sugiura T
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2631-6. PubMed ID: 18086767
[TBL] [Abstract][Full Text] [Related]
10. Serum Helicobacter pylori CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan.
Shiota S; Murakami K; Okimoto T; Kodama M; Yamaoka Y
J Gastroenterol Hepatol; 2014 Jan; 29(1):67-73. PubMed ID: 24033876
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
Germaná B; Di Mario F; Cavallaro LG; Moussa AM; Lecis P; Liatoupolou S; Comparato G; Carloni C; Bertiato G; Battiestel M; Papa N; Aragona G; Cavestro GM; Iori V; Merli R; Bertolini S; Caruana P; Franzé A
Dig Liver Dis; 2005 Jul; 37(7):501-8. PubMed ID: 15975537
[TBL] [Abstract][Full Text] [Related]
12. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis.
Nasrollahzadeh D; Aghcheli K; Sotoudeh M; Shakeri R; Persson EC; Islami F; Kamangar F; Abnet CC; Boffetta P; Engstrand L; Dawsey SM; Malekzadeh R; Ye W
PLoS One; 2011; 6(10):e26957. PubMed ID: 22066020
[TBL] [Abstract][Full Text] [Related]
13. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
14. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
15. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer.
Yamada S; Kato S; Matsuhisa T; Makonkawkeyoon L; Yoshida M; Chakrabandhu T; Lertprasertsuk N; Suttharat P; Chakrabandhu B; Nishiumi S; Chongraksut W; Azuma T
World J Gastroenterol; 2013 May; 19(19):2941-9. PubMed ID: 23704827
[TBL] [Abstract][Full Text] [Related]
16. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
17. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study.
Väänänen H; Vauhkonen M; Helske T; Kääriäinen I; Rasmussen M; Tunturi-Hihnala H; Koskenpato J; Sotka M; Turunen M; Sandström R; Ristikankare M; Jussila A; Sipponen P
Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):885-91. PubMed ID: 12867799
[TBL] [Abstract][Full Text] [Related]
18. [Serological diagnosis of atrophic gastritis with a combination of pepsinogen I and II, gastrin-17 and anti-Helicobacter pylori antibodies].
Valle Muñoz J; Artaza Varasa T; López Pardo R; Rodríguez Merlo R; Pérez Grueso MJ; Martín Escobedo R; Alcántara Torres M; Cuena Boy R; Carrobles Jiménez JM
Gastroenterol Hepatol; 2007 Dec; 30(10):567-71. PubMed ID: 18028850
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.
Leja M; Cine E; Rudzite D; Vilkoite I; Huttunen T; Daugule I; Rumba-Rozenfelde I; Pimanov S; Liepniece-Karele I; Pahomova J; Purmalis K; Eglitis J; Pirags V; Dzerve V; Erglis A
Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1410-7. PubMed ID: 23114744
[TBL] [Abstract][Full Text] [Related]
20. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
